Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
Health & Biotech
ASX Health Stocks: 4DX shares continue ascent after signing a deal with global player, Philips
Health & Biotech
Dimerix gains on China drug application approval
Health & Biotech
Melodiol enjoys milestone 2023 as subsidiaries bank profits
Health & Biotech
Wellnex Life to rise 117pc in next 12 months forecasts Vested Equities
Health & Biotech
‘Fundamentals for success in place’: Myriad drives growth as AROA reports strong first half
Health & Biotech
ASX Health Stocks: Nova Eye catches a break as US Medicare reimbursement decision deferred until March
Health & Biotech
‘Exceeded our expectations’: EZZ focuses on robust growth after strong FY23
Health & Biotech
“Market is going to be surprised” as Firebrick Pharma set to launch antiviral nasal spray, Nasodine
Health & Biotech
ASX Health Stocks: EMvision calls its AI brain scanner ’emu’
Health & Biotech
ScoPo’s Powerplays: ASX health stocks flat as a pancake but hopes still of Christmas rally
Health & Biotech
ASX Health Stocks: Rhythm Bio says new research in lung cancer is warranted after this finding
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.